Current and future treatment options in XXXX .

@entity1 @entity3336 @entity171 @entity174 @entity170 @entity460 @entity176 @entity461 @entity560
PURPOSE: The incidence of @entity170 -related @entity174 will increase substantially over the coming decades as the population ages globally. This has important economic and public health implications, contributing substantially to morbidity and excess mortality in this population. METHODS: When prescribing for older @entity1 the effectiveness profile of drugs needs to be balanced against their tolerability in individual @entity1 . RESULTS: Currently we have good anti- @entity174 data to support the use of many available anti-resorptive and anabolic drugs including @entity171 , @entity176 and recombinant @entity1 @entity461 . We also have evidence to demonstrate the importance of @entity460 and @entity560 repletion in these @entity1 . However, in recent years our understanding of normal bone physiology and the mechanisms underlying the development of @entity170 has significantly advanced and this has led to the development of new therapies. Novel agents, particularly denosumab, but also inhibitors of @entity3336 and anabolic agents that act on Wnt signalling, will increase the therapeutic options for clinicians in the coming years. CONCLUSION: This review discusses the evidence supporting the use of currently available treatment options for @entity170 and potential future advances in drug therapy. Particular consideration should be given when prescribing for certain older @entity1 who have issues with compliance or tolerance and also in those with co-morbidities or levels of frailty that may restrict the choice of therapy. Understanding the evidence for the benefit and possible harm of @entity170 treatments is critical to appropriate management of this @entity1 population.
